Ocugen Pharma (OCGN) - Bozor kapitallashuvining balans qiymatiga nisbati

Ocugen, Inc. (OCGN) - korporativ logo

Ocugen, Inc. (OCGN) rahbariyati ko'rish qobiliyatining yo'qolishiga qarshi kurashish uchun genlarni tuzatish usullarini faol ravishda ishlab chiqmoqda va R&D hisobotlarida shaffoflikni namoyish etmoqda, garchi mablag'larning sarflanish sur'ati yuqori bo'lib qolayotgan bo'lsa-da. I/II bosqich sinovlari natijalari kutilishi va joriy xarajatlar allaqachon narxga kiritilgan bo'lib, kompaniyaning baholanishi -15.57 darajasida turibdi. GURU.Markets platformasi grafigidagi ushbu narx harakati vaksinalar va AQSh bozori uchun noyob terapevtik tizim yaratayotgan biotexnologiya firmasi kotirovkalarini aks ettiradi.

Ocugen Pharma (OCGN) Kapitallashuvning balans qiymatiga nisbati: 04.07.2022 - 29.10.2026 davri uchun

Ocugen, Inc. kompaniyasining tahliliy kesimlari

- bozor qiymati va tahlilchilarning maqsadli prognozi:
Narx grafigi Ocugen, Inc.|OCGN - Investitsiya uylarining umumiy prognozi
- bozor kapitallashuvi ko'rsatkichlari:
Bozor kapitallashuvi Ocugen Corp|OCGN - Biznes qiymati
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
Bitta aksiya uchun sof aktivlar Ocugen|OCGN - Buxgalteriya kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati ocugen.com|OCGN - Kompaniyaning umumiy aktivlari
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Qarzning xususiy kapitalga nisbati Ocugen, Inc.|OCGN - Uzoq muddatli majburiyatlarning kapitalga nisbati|Qisqa muddatli qarzning kapitalga nisbati Ocugen Corp|OCGN - Kompaniyaning umumiy qarzi|Qarzning balans qiymatiga nisbati Ocugen Corp|OCGN - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli qarzlari Ocugen|Tezkor likvidlik koeffitsiyenti ocugen.com
- foyda va bozor multiplikatorlari tafsilotlari:
OCGN - Kompaniyaning sof daromadi
Kompaniyaning asosiy tahlili:Ocugen, Inc., OCGN
Ocugen Inc ishlab chiqargan mahsulot

Ocugen, Inc. (OCGN) samaradorligini ob'ektiv baholash uchun investorlarga biznesning joriy bozor qiymatini uning haqiqiy sof aktivlari bilan solishtirish zarurdir. Bozor qiymatining buxgalteriya qiymatiga nisbati (market-to-book ratio) dagi o'zgarishlarni tahlil qilish orqali, kompaniyaning gen terapiyasi va vaksinalashdagi patentlarini o'z ichiga olgan intellektual kapitali uchun to'langan premium miqdorini aniqlash mumkin, bu esa tendentsiya teskari tomonga o'zgarganda risklarni minimallashtirish uchun juda muhimdir.

Raqobatchilar tahlili

Tempus Labs (TEM) - Bozor qiymatining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati QGEN|IONS (Ionis) - Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati RGEN (Repligen Corp)|Bozor qiymatining balans qiymatiga nisbati Avidity (RNA)|CRISPR - Kapitallashuvning balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati WGS (GeneDx Holdings Corp.)|Bozor kapitallashuvining balans qiymatiga nisbati ultragenyx.com RARE|BEAM - Bozor qiymatining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti Sarepta Therapeutics|TWST: Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning sof aktivlarga nisbati 10x|Kapitallashuvning sof aktivlarga nisbati NTLA|Bozor kapitallashuvining balans qiymatiga nisbati stoketherapeutics.com|Bozor kapitallashuvining balans qiymatiga nisbati BLFS|Wave Life Sciences Ltd (WVE) - Bozor qiymatining xususiy kapitalga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati MAZE (Maze Tx)|Sionna Corp (SION) - Bozor qiymatining balans qiymatiga koeffitsiyenti|PRME - Bozor qiymatining balans qiymatiga nisbati|TSHA (tayshagtx.com) - Kapitallashuvning balans qiymatiga nisbati|QURE (uniQure) - Kapitallashuvning sof aktivlarga nisbati|MeiraGTx Holdings - Balans qiymatiga nisbatan bozor qiymati|RGNX (Regenxbio) - Bozor kapitallashuvining balans qiymatiga nisbati|Solid Corp (SLDB) - Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati Pacific Biosciences (PACB)|benitec.com - Kapitallashuvning balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati DSGN (Design Therapeutics, Inc.)|RCKT - Kapitallashuvning sof aktivlarga nisbati|FDMT: Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi Lexeo Therapeutics LXEO|korrobio.com (KRRO) - Bozor qiymatining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti editasmedicine.com (EDIT)|SLN (Silence Therapeutics plc) - Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning sof aktivlarga nisbati ProQR Therapeutics NV (PRQR)|Bozor kapitallashuvining balans qiymatiga nisbati CDXS|Sangamo BioSciences (SGMO) - Bozor qiymatining xususiy kapitalga nisbati|Bozor qiymatining balans qiymatiga nisbati Nautilus Bio NAUT|MGX: Kapitallashuvning balans qiymatiga nisbati|Precision BioSciences - Bozor kapitallashuvining balans qiymatiga nisbati|GBIO (Generation Bio Co.) - Kapitallashuvning balans qiymatiga nisbati|Boundless Bio, Inc (BOLD) - Bozor qiymatining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati XCUR|IMNN (Imunon Inc) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati RXi Pharmaceuticals|Bozor qiymatining balans qiymatiga nisbati Mustang Bio, Inc. (MBIO)|RNAZ - Bozor qiymatining balans qiymatiga koeffitsiyenti|Bozor kapitallashuvining balans qiymatiga nisbati BNGO (Bionano Genomics)|APDN - Kapitallashuvning sof aktivlarga nisbati|BLUE: Kapitallashuvning sof aktivlarga nisbati|IPA - Bozor kapitallashuvining balans qiymatiga nisbati|OMGA: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining xususiy kapitalga nisbati Singular Genomics Systems, Inc. OMIC|RGLS (Regulus Therapeutics Inc) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti Syros Pharmaceuticals, Inc SYRS|Bozor qiymatining balans qiymatiga nisbati Telesis Bio, Inc. (TBIO)|traconpharma.com - Kapitallashuvning balans qiymatiga nisbati|Unity Biotechnology, Inc. - Kapitallashuvning sof aktivlarga nisbati